SCHEMBL29520705

SCHEMBL29520705

CC(C)N(C)n1ncc2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.47
MEN1 O00255 2/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RECQL P46063 1/20 0.40
CYP1A2 P05177 1/20 0.37
ADRA2A P08913 2/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6008594 0.76 SLC6A2 (0.46) SLC6A2MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL6006426 0.76 SLC6A2 (0.46) SLC6A2MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL29520621 0.73 SLC6A2 (0.63) SLC6A2MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL29520993 0.71 SLC6A2 (0.45) SLC6A2MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL28001615 0.71 ELANE (0.49) MEN1RAB9AKMT2ASMN1; SMN2KDM4E
SCHEMBL29350890 0.71 RECQL (0.43) SLC6A2MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL878425 0.71 RECQL (0.43) SLC6A2MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL20622947 0.68 RECQL (0.41) SLC6A2MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL21276545 0.68 RECQL (0.41) SLC6A2MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL29311539 0.68 RECQL (0.41) SLC6A2MEN1RAB9AKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649255-B2 Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same 1ST Biotherapeutics, Inc. (KR) 2023-05-16 US disclosed
US-20220098193-A1 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME 1ST Biotherapeutics, Inc. 2022-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649255-B2 Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same IP6K1, HIPK1, IP6K3 SLC6A2 4822/4885MEN1 2174/4885RAB9A 1928/4885
US-20220098193-A1 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME IP6K1, HIPK1, IP6K3 SLC6A2 4822/4885MEN1 2174/4885RAB9A 1928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.